贾纳斯激酶
医学
杰纳斯
免疫学
细胞因子
纳米技术
材料科学
作者
William Damsky,Danielle M. Peterson,Julie Y. Ramseier,Badr Al‐Bawardy,Hyung J. Chun,Deborah D. Proctor,Vibeke Strand,Richard Anthony Flavell,Brett King
标识
DOI:10.1016/j.jaci.2020.10.022
摘要
Autoimmune and inflammatory diseases are common and diverse, and they can affect nearly any organ system. Much of the pathogenesis of these diseases is related to dysregulated cytokine activity. Historically, autoimmune and inflammatory diseases have been treated with medications that nonspecifically suppress the immune system. mAbs that block the action of pathogenic cytokines emerged 2 decades ago and have become widely useful. More recently, agents that simultaneously block multiple pathogenic cytokines via inhibition of the downstream Janus kinase (JAK)–signal transducer and activator of transcription pathway have emerged and are becoming increasingly important. These small-molecule inhibitors, collectively termed JAK inhibitors, are US Food and Drug Administration–approved in a few autoimmune/inflammatory disorders and are being evaluated in many others. Here, we review the biology of the JAK–signal transducer and activator of transcription pathway and the use of JAK inhibitors to treat autoimmune and inflammatory diseases across medical subspecialties.
科研通智能强力驱动
Strongly Powered by AbleSci AI